The DNA testing firm 23andMe experienced a significant setback as its stock plummeted by 59% following the company's decision to file for bankruptcy protection and the resignation of its CEO. Initially a prominent player in Silicon Valley with a large consumer base, the company sought Chapter 11 bankruptcy after unsuccessful attempts to secure a buyer. Despite the CEO's efforts to acquire the company privately, the board turned down the offer and she stepped down. The company faced legal challenges, including a privacy breach and subsequent lawsuits, culminating in investigations by authorities in the UK and Canada. In the past, the FDA had also ordered 23andMe to stop marketing their tests due to unsubstantiated claims. Additionally, California customers were reminded of their rights to delete their genetic data from the company's database.